oleclumab (MEDI9447) / AstraZeneca  >>  Phase 1
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oleclumab (MEDI9447) / AstraZeneca
NCT03736473: A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Completed
1
6
Japan
MEDI9447 (oleclumab)
AstraZeneca
Advanced Solid Malignancies
06/19
06/19
NCT02740985: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Hourglass Jul 2018 - Dec 2018 : For advanced solid tumours
Completed
1
313
US
AZD4635, Durvalumab, MEDI4736, Abiraterone Acetate, Zytiga, Enzalutamide, Xtandi, Oleclumab, MEDI9447, Docetaxel, Taxotere
AstraZeneca
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
12/20
03/23
D6070C00001, NCT02503774: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Hourglass Jan 2022 - Dec 2022 : For advanced malignancies
Completed
1
192
US, RoW
Oleclumab, Durvalumab
MedImmune LLC
Solid Tumors
01/21
03/23
NCT03773666: A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Completed
1
12
US
Durvalumab, MEDI4736, Oleclumab, MEDI9447
Dana-Farber Cancer Institute, AstraZeneca
Muscle Invasive Bladder Cancer
02/21
08/21
NCT04261075: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Hourglass Jul 2022 - Dec 2022 : Data from trial for advanced solid tumors
Checkmark in combination with oleclumab
Jul 2020 - Jul 2020: in combination with oleclumab
Completed
1
57
Europe, US
IPH5201, durvalumab, oleclumab
MedImmune LLC
Advanced Solid Tumors
06/22
06/22
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Calendar Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
ARCHON-1, NCT03801902: Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), Trial

Recruiting
1
48
US
Accelerated Hypofractionated Radiation Therapy, AHF-RT, AHRT, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Magnetic Resonance Imaging of the Brain with and without Contrast, Brain Magnetic Resonance Imaging with and without Contrast, Brain MRI, Brain MRI with and without Contrast, Head MRI with and without Contrast, Monalizumab, Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody, IPH-2201, IPH2201, NN-8765, NN8765, NN8765-3658, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI), NRG Oncology
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
03/25
03/25

Download Options